Drugs@FDA: FDA-Approved Drugs
New Drug Application (NDA): 217188
Company: PFIZER
Company: PFIZER
| Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
|---|---|---|---|---|---|---|---|
| PAXLOVID (COPACKAGED) | NIRMATRELVIR; RITONAVIR | 150MG;100MG | TABLET;ORAL | Prescription | None | Yes | Yes |
| PAXLOVID (COPACKAGED) | NIRMATRELVIR; RITONAVIR | 300MG;100MG | TABLET;ORAL | Prescription | None | Yes | Yes |
Original Approvals or Tentative Approvals
| Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
|---|---|---|---|---|---|---|---|
| 05/25/2023 | ORIG-1 | Approval | Type 1 - New Molecular Entity | PRIORITY |
Label (PDF)
Letter (PDF) Review |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217188s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/217188Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217188Orig1s000TOC.cfm |
Supplements
| Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert | Note | Url |
|---|---|---|---|---|---|
| 02/12/2025 | SUPPL-10 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217188s010lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/217188Orig1s010ltr.pdf | |
| 11/19/2024 | SUPPL-9 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217188s009lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/217188Orig1s009ltr.pdf | |
| 01/31/2025 | SUPPL-8 | Efficacy-New Patient Population |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217188s008lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/217188Orig1s008ltr.pdf | |
| 09/12/2024 | SUPPL-6 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217188s006lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/217188Orig1s006ltr.pdf |
| Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert |
Note | Url |
|---|---|---|---|---|---|
| 02/12/2025 | SUPPL-10 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217188s010lbl.pdf | |
| 01/31/2025 | SUPPL-8 | Efficacy-New Patient Population | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217188s008lbl.pdf | |
| 11/19/2024 | SUPPL-9 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217188s009lbl.pdf | |
| 09/12/2024 | SUPPL-6 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217188s006lbl.pdf | |
| 05/25/2023 | ORIG-1 | Approval | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217188s000lbl.pdf |